Cargando…
Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus
Sodium glucose cotransporter 2 (SGLT2), a type of membrane protein highly expressed in the kidney, can regulate plasma glucose through the glomerular filtration process by reabsorption from the kidney. SGLT2 inhibitors, which are newly developed oral antidiabetic drugs, can play a role in liver dise...
Autores principales: | Zhang, Enxiang, Zhao, Yang, Hu, Hongbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122372/ https://www.ncbi.nlm.nih.gov/pubmed/34027265 http://dx.doi.org/10.1002/hep4.1611 |
Ejemplares similares
-
Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
por: Dokmak, Amr, et al.
Publicado: (2019) -
Effects of a sodium‐glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies
por: Akuta, Norio, et al.
Publicado: (2017) -
Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Euh, Won, et al.
Publicado: (2021) -
Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan
por: Yano, Kota, et al.
Publicado: (2020) -
Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
por: Mantovani, Alessandro, et al.
Publicado: (2020)